Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ijms19061816 http://scihub22266oqcxt.onion/10.3390/ijms19061816 C6032159!6032159!29925789     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29925789.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Int+J+Mol+Sci 2018 ; 19 (6): ä Nephropedia Template TP {{tp|p=29925789|t=2018. Diabetic Retinopathy: Pathophysiology and Treatments |pdf=|usr=}}{{29925789}} gab.com Text Diabetic Retinopathy: Pathophysiology and Treatments JO: Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=29925789 #FOAvip Diabetic retinopathy (DR) is the most common complication of diabetes mellitus (DM). It has long been recognized as a microvascular disease. The diagnosis of DR relies on the detection of microvascular lesions. The treatment of DR remains challenging. The advent of anti-vascular endothelial growth factor (VEGF) therapy demonstrated remarkable clinical benefits in DR patients; however, the majority of patients failed to achieve clinically-significant visual improvement. Therefore, there is an urgent need for the development of new treatments. Laboratory and clinical evidence showed that in addition to microvascular changes, inflammation and retinal neurodegeneration may contribute to diabetic retinal damage in the early stages of DR. Further investigation of the underlying molecular mechanisms may provide targets for the development of new early interventions. Here, we present a review of the current understanding and new insights into pathophysiology in DR, as well as clinical treatments for DR patients. Recent laboratory findings and related clinical trials are also reviewed. Twit Text FOAVip Diabetic Retinopathy: Pathophysiology and Treatments ????Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=29925789 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29925789 #FOAvip English Wikipedia <ref>{{Cite pmid|29925789}}</ref> Diabetic Retinopathy: Pathophysiology and Treatments #MMPMID29925789 Wang W; Lo ACY Int J Mol Sci 2018[Jun]; 19 (6): ä PMID29925789show ga Diabetic retinopathy (DR) is the most common complication of diabetes mellitus (DM). It has long been recognized as a microvascular disease. The diagnosis of DR relies on the detection of microvascular lesions. The treatment of DR remains challenging. The advent of anti-vascular endothelial growth factor (VEGF) therapy demonstrated remarkable clinical benefits in DR patients; however, the majority of patients failed to achieve clinically-significant visual improvement. Therefore, there is an urgent need for the development of new treatments. Laboratory and clinical evidence showed that in addition to microvascular changes, inflammation and retinal neurodegeneration may contribute to diabetic retinal damage in the early stages of DR. Further investigation of the underlying molecular mechanisms may provide targets for the development of new early interventions. Here, we present a review of the current understanding and new insights into pathophysiology in DR, as well as clinical treatments for DR patients. Recent laboratory findings and related clinical trials are also reviewed. äDiabetic Retinopathy: Pathophysiology and Treatments (epmc).pdf DeepDyve Pubget Overpricing